NV-387 / NanoViricides - LARVOL DELTA

Remdesivir-bisPropionate, a better derivative of remdesivir against SARS-CoV-2: Comparison of in vitro and in vivo PK/PD Study as well as its therapeutic potential. (PubMed, PLoS One) - "In order to increase the protective strength of remdesivir we took couple of approaches, one, to make an alternative but better derivative of remdesivir as remdesivir bis-propionate, and the other is to use our platform- designed biopolymer (NV387) to protect remdesivir compound from degradation in presence of plasma. (3) The antiviral activity is also increased against NL-63 infection to rat model, compared to naked and/or encapsulated remdesivir. (4) The antiviral efficacy of the remdesivir pro-drug, therefore, can be mathematically drawn as follows: remdesivir-bP-encapsulated > remdesivir-encapsulated > remdesivir-bP > remdesivir."

Clinical • Journal • PK/PD data • Preclinical • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

NanoViricides, Inc…announced today that it has filed an application for "Orphan Drug Designation" (ODD) for NV-387 as a Treatment for Measles with the US FDA Office of Orphan Products Development (OOPD). (Yahoo Finance)

Orphan drug • Measles

NanoViricides Has Received Approval to Start Phase II Clinical Trial of NV-387 for the Treatment of MPox by the Regulatory Agency ACOREP of the Democratic Republic of Congo (Le Lézard) - "We have now completed submission of substantial required documentation in the draft forms as requested. We are now in the process of compiling all of this documentation together into the final form Clinical Trial Application, along with associated certifications and disclosures."

New P2 trial • Infectious Disease

A Drug that Could Reduce Metastatic Cancer Resurgence due to Its Anti-Inflammatory Effects in Viral Infections is in Clinical Trials (ACCESS Newswire) - "NanoViricides...reports that its broad-spectrum antiviral drug NV-387 could help reduce resurgence of metastatic cancer caused by awakening of 'sleeping' cancer cells due to viral infections. NV-387 has successfully completed a Phase I clinical trial and is being advanced into Phase II clinical trials."

Clinical • Trial status • Oncology